1 Market Overview

1.1 Product Overview and Scope of Paclitaxel and Its Analogue in Anticarcinoma Drugs

1.2 Classification of Paclitaxel and Its Analogue in Anticarcinoma Drugs by Type

1.2.1 Overview: Global Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Size by Type: 2017 Versus 2021 Versus 2028

1.2.2 Global Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue Market Share by Type in 2021

1.2.3 Paclitaxel

1.2.4 Docetaxel

1.2.5 Liposome Paclitaxel

1.2.6 Protein-bound Paclitaxel

1.3 Global Paclitaxel and Its Analogue in Anticarcinoma Drugs Market by Application

1.3.1 Overview: Global Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Size by Application: 2017 Versus 2021 Versus 2028

1.3.2 Ovarian Cancer

1.3.3 Breast Cancer

1.3.4 Cervical Cancer

1.3.5 Pancreatic Cancer

1.3.6 Non-small Cell Lung Cancer

1.3.7 Other

1.4 Global Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Size & Forecast

1.5 Global Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Size and Forecast by Region

1.5.1 Global Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Size by Region: 2017 VS 2021 VS 2028

1.5.2 Global Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Size by Region, (2017-2022)

1.5.3 North America Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Size and Prospect (2017-2028)

1.5.4 Europe Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Size and Prospect (2017-2028)

1.5.5 Asia-Pacific Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Size and Prospect (2017-2028)

1.5.6 South America Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Size and Prospect (2017-2028)

1.5.7 Middle East and Africa Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Size and Prospect (2017-2028)

1.6 Market Drivers, Restraints and Trends

1.6.1 Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Drivers

1.6.2 Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Restraints

1.6.3 Paclitaxel and Its Analogue in Anticarcinoma Drugs Trends Analysis

2 Company Profiles

2.1 Bristol-Myers Squibb

2.1.1 Bristol-Myers Squibb Details

2.1.2 Bristol-Myers Squibb Major Business

2.1.3 Bristol-Myers Squibb Paclitaxel and Its Analogue in Anticarcinoma Drugs Product and Solutions

2.1.4 Bristol-Myers Squibb Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.1.5 Bristol-Myers Squibb Recent Developments and Future Plans

2.2 Celgene Corporation

2.2.1 Celgene Corporation Details

2.2.2 Celgene Corporation Major Business

2.2.3 Celgene Corporation Paclitaxel and Its Analogue in Anticarcinoma Drugs Product and Solutions

2.2.4 Celgene Corporation Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.2.5 Celgene Corporation Recent Developments and Future Plans

2.3 Hospira

2.3.1 Hospira Details

2.3.2 Hospira Major Business

2.3.3 Hospira Paclitaxel and Its Analogue in Anticarcinoma Drugs Product and Solutions

2.3.4 Hospira Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.3.5 Hospira Recent Developments and Future Plans

2.4 Biological E.

2.4.1 Biological E. Details

2.4.2 Biological E. Major Business

2.4.3 Biological E. Paclitaxel and Its Analogue in Anticarcinoma Drugs Product and Solutions

2.4.4 Biological E. Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.4.5 Biological E. Recent Developments and Future Plans

2.5 Taj Accura

2.5.1 Taj Accura Details

2.5.2 Taj Accura Major Business

2.5.3 Taj Accura Paclitaxel and Its Analogue in Anticarcinoma Drugs Product and Solutions

2.5.4 Taj Accura Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.5.5 Taj Accura Recent Developments and Future Plans

2.6 Khandelwal Laboratories

2.6.1 Khandelwal Laboratories Details

2.6.2 Khandelwal Laboratories Major Business

2.6.3 Khandelwal Laboratories Paclitaxel and Its Analogue in Anticarcinoma Drugs Product and Solutions

2.6.4 Khandelwal Laboratories Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.6.5 Khandelwal Laboratories Recent Developments and Future Plans

2.7 Luye Pharma

2.7.1 Luye Pharma Details

2.7.2 Luye Pharma Major Business

2.7.3 Luye Pharma Paclitaxel and Its Analogue in Anticarcinoma Drugs Product and Solutions

2.7.4 Luye Pharma Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.7.5 Luye Pharma Recent Developments and Future Plans

2.8 Beijing Youcare

2.8.1 Beijing Youcare Details

2.8.2 Beijing Youcare Major Business

2.8.3 Beijing Youcare Paclitaxel and Its Analogue in Anticarcinoma Drugs Product and Solutions

2.8.4 Beijing Youcare Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.8.5 Beijing Youcare Recent Developments and Future Plans

2.9 Beijing Union

2.9.1 Beijing Union Details

2.9.2 Beijing Union Major Business

2.9.3 Beijing Union Paclitaxel and Its Analogue in Anticarcinoma Drugs Product and Solutions

2.9.4 Beijing Union Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.9.5 Beijing Union Recent Developments and Future Plans

2.10 Haiyao

2.10.1 Haiyao Details

2.10.2 Haiyao Major Business

2.10.3 Haiyao Paclitaxel and Its Analogue in Anticarcinoma Drugs Product and Solutions

2.10.4 Haiyao Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.10.5 Haiyao Recent Developments and Future Plans

2.11 Chuntch

2.11.1 Chuntch Details

2.11.2 Chuntch Major Business

2.11.3 Chuntch Paclitaxel and Its Analogue in Anticarcinoma Drugs Product and Solutions

2.11.4 Chuntch Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.11.5 Chuntch Recent Developments and Future Plans

2.12 Hengrui Medicine

2.12.1 Hengrui Medicine Details

2.12.2 Hengrui Medicine Major Business

2.12.3 Hengrui Medicine Paclitaxel and Its Analogue in Anticarcinoma Drugs Product and Solutions

2.12.4 Hengrui Medicine Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.12.5 Hengrui Medicine Recent Developments and Future Plans

2.13 Sanofi

2.13.1 Sanofi Details

2.13.2 Sanofi Major Business

2.13.3 Sanofi Paclitaxel and Its Analogue in Anticarcinoma Drugs Product and Solutions

2.13.4 Sanofi Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.13.5 Sanofi Recent Developments and Future Plans

2.14 Qilu Pharma

2.14.1 Qilu Pharma Details

2.14.2 Qilu Pharma Major Business

2.14.3 Qilu Pharma Paclitaxel and Its Analogue in Anticarcinoma Drugs Product and Solutions

2.14.4 Qilu Pharma Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.14.5 Qilu Pharma Recent Developments and Future Plans

2.15 Shenzhen Main Luck Pharma

2.15.1 Shenzhen Main Luck Pharma Details

2.15.2 Shenzhen Main Luck Pharma Major Business

2.15.3 Shenzhen Main Luck Pharma Paclitaxel and Its Analogue in Anticarcinoma Drugs Product and Solutions

2.15.4 Shenzhen Main Luck Pharma Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.15.5 Shenzhen Main Luck Pharma Recent Developments and Future Plans

2.16 Jiangsu Aosaikang Pharma

2.16.1 Jiangsu Aosaikang Pharma Details

2.16.2 Jiangsu Aosaikang Pharma Major Business

2.16.3 Jiangsu Aosaikang Pharma Paclitaxel and Its Analogue in Anticarcinoma Drugs Product and Solutions

2.16.4 Jiangsu Aosaikang Pharma Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.16.5 Jiangsu Aosaikang Pharma Recent Developments and Future Plans

2.17 CSPC Pharmaceutical

2.17.1 CSPC Pharmaceutical Details

2.17.2 CSPC Pharmaceutical Major Business

2.17.3 CSPC Pharmaceutical Paclitaxel and Its Analogue in Anticarcinoma Drugs Product and Solutions

2.17.4 CSPC Pharmaceutical Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.17.5 CSPC Pharmaceutical Recent Developments and Future Plans

2.18 Aosaikang Pharm

2.18.1 Aosaikang Pharm Details

2.18.2 Aosaikang Pharm Major Business

2.18.3 Aosaikang Pharm Paclitaxel and Its Analogue in Anticarcinoma Drugs Product and Solutions

2.18.4 Aosaikang Pharm Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.18.5 Aosaikang Pharm Recent Developments and Future Plans

3 Market Competition, by Players

3.1 Global Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue and Share by Players (2019, 2020, 2021, and 2022)

3.2 Market Concentration Rate

3.2.1 Top 3 Paclitaxel and Its Analogue in Anticarcinoma Drugs Players Market Share in 2021

3.2.2 Top 10 Paclitaxel and Its Analogue in Anticarcinoma Drugs Players Market Share in 2021

3.2.3 Market Competition Trend

3.3 Paclitaxel and Its Analogue in Anticarcinoma Drugs Players Head Office, Products and Services Provided

3.4 Paclitaxel and Its Analogue in Anticarcinoma Drugs Mergers & Acquisitions

3.5 Paclitaxel and Its Analogue in Anticarcinoma Drugs New Entrants and Expansion Plans

4 Market Size Segment by Type

4.1 Global Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue and Market Share by Type (2017-2022)

4.2 Global Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Forecast by Type (2023-2028)

5 Market Size Segment by Application

5.1 Global Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue Market Share by Application (2017-2022)

5.2 Global Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Forecast by Application (2023-2028)

6 North America by Country, by Type, and by Application

6.1 North America Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue by Type (2017-2028)

6.2 North America Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue by Application (2017-2028)

6.3 North America Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Size by Country

6.3.1 North America Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue by Country (2017-2028)

6.3.2 United States Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Size and Forecast (2017-2028)

6.3.3 Canada Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Size and Forecast (2017-2028)

6.3.4 Mexico Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Size and Forecast (2017-2028)

7 Europe by Country, by Type, and by Application

7.1 Europe Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue by Type (2017-2028)

7.2 Europe Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue by Application (2017-2028)

7.3 Europe Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Size by Country

7.3.1 Europe Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue by Country (2017-2028)

7.3.2 Germany Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Size and Forecast (2017-2028)

7.3.3 France Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Size and Forecast (2017-2028)

7.3.4 United Kingdom Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Size and Forecast (2017-2028)

7.3.5 Russia Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Size and Forecast (2017-2028)

7.3.6 Italy Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Size and Forecast (2017-2028)

8 Asia-Pacific by Region, by Type, and by Application

8.1 Asia-Pacific Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue by Type (2017-2028)

8.2 Asia-Pacific Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue by Application (2017-2028)

8.3 Asia-Pacific Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Size by Region

8.3.1 Asia-Pacific Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue by Region (2017-2028)

8.3.2 China Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Size and Forecast (2017-2028)

8.3.3 Japan Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Size and Forecast (2017-2028)

8.3.4 South Korea Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Size and Forecast (2017-2028)

8.3.5 India Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Size and Forecast (2017-2028)

8.3.6 Southeast Asia Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Size and Forecast (2017-2028)

8.3.7 Australia Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Size and Forecast (2017-2028)

9 South America by Country, by Type, and by Application

9.1 South America Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue by Type (2017-2028)

9.2 South America Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue by Application (2017-2028)

9.3 South America Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Size by Country

9.3.1 South America Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue by Country (2017-2028)

9.3.2 Brazil Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Size and Forecast (2017-2028)

9.3.3 Argentina Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Size and Forecast (2017-2028)

10 Middle East & Africa by Country, by Type, and by Application

10.1 Middle East & Africa Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue by Type (2017-2028)

10.2 Middle East & Africa Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue by Application (2017-2028)

10.3 Middle East & Africa Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Size by Country

10.3.1 Middle East & Africa Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue by Country (2017-2028)

10.3.2 Turkey Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Size and Forecast (2017-2028)

10.3.3 Saudi Arabia Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Size and Forecast (2017-2028)

10.3.4 UAE Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Size and Forecast (2017-2028)

11 Research Findings and Conclusion

12 Appendix

12.1 Methodology

12.2 Research Process and Data Source

12.3 Disclaimer

List of Tables

Table 1. Global Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue by Type, (USD Million), 2017 VS 2021 VS 2028

Table 2. Global Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue by Application, (USD Million), 2017 VS 2021 VS 2028

Table 3. Global Market Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue (Million USD) Comparison by Region (2017 VS 2021 VS 2028)

Table 4. Global Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue (USD Million) by Region (2017-2022)

Table 5. Global Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue Market Share by Region (2023-2028)

Table 6. Bristol-Myers Squibb Corporate Information, Head Office, and Major Competitors

Table 7. Bristol-Myers Squibb Major Business

Table 8. Bristol-Myers Squibb Paclitaxel and Its Analogue in Anticarcinoma Drugs Product and Solutions

Table 9. Bristol-Myers Squibb Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 10. Celgene Corporation Corporate Information, Head Office, and Major Competitors

Table 11. Celgene Corporation Major Business

Table 12. Celgene Corporation Paclitaxel and Its Analogue in Anticarcinoma Drugs Product and Solutions

Table 13. Celgene Corporation Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 14. Hospira Corporate Information, Head Office, and Major Competitors

Table 15. Hospira Major Business

Table 16. Hospira Paclitaxel and Its Analogue in Anticarcinoma Drugs Product and Solutions

Table 17. Hospira Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 18. Biological E. Corporate Information, Head Office, and Major Competitors

Table 19. Biological E. Major Business

Table 20. Biological E. Paclitaxel and Its Analogue in Anticarcinoma Drugs Product and Solutions

Table 21. Biological E. Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 22. Taj Accura Corporate Information, Head Office, and Major Competitors

Table 23. Taj Accura Major Business

Table 24. Taj Accura Paclitaxel and Its Analogue in Anticarcinoma Drugs Product and Solutions

Table 25. Taj Accura Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 26. Khandelwal Laboratories Corporate Information, Head Office, and Major Competitors

Table 27. Khandelwal Laboratories Major Business

Table 28. Khandelwal Laboratories Paclitaxel and Its Analogue in Anticarcinoma Drugs Product and Solutions

Table 29. Khandelwal Laboratories Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 30. Luye Pharma Corporate Information, Head Office, and Major Competitors

Table 31. Luye Pharma Major Business

Table 32. Luye Pharma Paclitaxel and Its Analogue in Anticarcinoma Drugs Product and Solutions

Table 33. Luye Pharma Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 34. Beijing Youcare Corporate Information, Head Office, and Major Competitors

Table 35. Beijing Youcare Major Business

Table 36. Beijing Youcare Paclitaxel and Its Analogue in Anticarcinoma Drugs Product and Solutions

Table 37. Beijing Youcare Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 38. Beijing Union Corporate Information, Head Office, and Major Competitors

Table 39. Beijing Union Major Business

Table 40. Beijing Union Paclitaxel and Its Analogue in Anticarcinoma Drugs Product and Solutions

Table 41. Beijing Union Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 42. Haiyao Corporate Information, Head Office, and Major Competitors

Table 43. Haiyao Major Business

Table 44. Haiyao Paclitaxel and Its Analogue in Anticarcinoma Drugs Product and Solutions

Table 45. Haiyao Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 46. Chuntch Corporate Information, Head Office, and Major Competitors

Table 47. Chuntch Major Business

Table 48. Chuntch Paclitaxel and Its Analogue in Anticarcinoma Drugs Product and Solutions

Table 49. Chuntch Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 50. Hengrui Medicine Corporate Information, Head Office, and Major Competitors

Table 51. Hengrui Medicine Major Business

Table 52. Hengrui Medicine Paclitaxel and Its Analogue in Anticarcinoma Drugs Product and Solutions

Table 53. Hengrui Medicine Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 54. Sanofi Corporate Information, Head Office, and Major Competitors

Table 55. Sanofi Major Business

Table 56. Sanofi Paclitaxel and Its Analogue in Anticarcinoma Drugs Product and Solutions

Table 57. Sanofi Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 58. Qilu Pharma Corporate Information, Head Office, and Major Competitors

Table 59. Qilu Pharma Major Business

Table 60. Qilu Pharma Paclitaxel and Its Analogue in Anticarcinoma Drugs Product and Solutions

Table 61. Qilu Pharma Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 62. Shenzhen Main Luck Pharma Corporate Information, Head Office, and Major Competitors

Table 63. Shenzhen Main Luck Pharma Major Business

Table 64. Shenzhen Main Luck Pharma Paclitaxel and Its Analogue in Anticarcinoma Drugs Product and Solutions

Table 65. Shenzhen Main Luck Pharma Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 66. Jiangsu Aosaikang Pharma Corporate Information, Head Office, and Major Competitors

Table 67. Jiangsu Aosaikang Pharma Major Business

Table 68. Jiangsu Aosaikang Pharma Paclitaxel and Its Analogue in Anticarcinoma Drugs Product and Solutions

Table 69. Jiangsu Aosaikang Pharma Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 70. CSPC Pharmaceutical Corporate Information, Head Office, and Major Competitors

Table 71. CSPC Pharmaceutical Major Business

Table 72. CSPC Pharmaceutical Paclitaxel and Its Analogue in Anticarcinoma Drugs Product and Solutions

Table 73. CSPC Pharmaceutical Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 74. Aosaikang Pharm Corporate Information, Head Office, and Major Competitors

Table 75. Aosaikang Pharm Major Business

Table 76. Aosaikang Pharm Paclitaxel and Its Analogue in Anticarcinoma Drugs Product and Solutions

Table 77. Aosaikang Pharm Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 78. Global Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue (USD Million) by Players (2019, 2020, 2021, and 2022)

Table 79. Global Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue Share by Players (2019, 2020, 2021, and 2022)

Table 80. Breakdown of Paclitaxel and Its Analogue in Anticarcinoma Drugs by Company Type (Tier 1, Tier 2 and Tier 3)

Table 81. Paclitaxel and Its Analogue in Anticarcinoma Drugs Players Head Office, Products and Services Provided

Table 82. Paclitaxel and Its Analogue in Anticarcinoma Drugs Mergers & Acquisitions in the Past Five Years

Table 83. Paclitaxel and Its Analogue in Anticarcinoma Drugs New Entrants and Expansion Plans

Table 84. Global Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue (USD Million) by Type (2017-2022)

Table 85. Global Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue Share by Type (2017-2022)

Table 86. Global Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue Forecast by Type (2023-2028)

Table 87. Global Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue by Application (2017-2022)

Table 88. Global Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue Forecast by Application (2023-2028)

Table 89. North America Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue by Type (2017-2022) & (USD Million)

Table 90. North America Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue by Type (2023-2028) & (USD Million)

Table 91. North America Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue by Application (2017-2022) & (USD Million)

Table 92. North America Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue by Application (2023-2028) & (USD Million)

Table 93. North America Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue by Country (2017-2022) & (USD Million)

Table 94. North America Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue by Country (2023-2028) & (USD Million)

Table 95. Europe Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue by Type (2017-2022) & (USD Million)

Table 96. Europe Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue by Type (2023-2028) & (USD Million)

Table 97. Europe Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue by Application (2017-2022) & (USD Million)

Table 98. Europe Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue by Application (2023-2028) & (USD Million)

Table 99. Europe Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue by Country (2017-2022) & (USD Million)

Table 100. Europe Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue by Country (2023-2028) & (USD Million)

Table 101. Asia-Pacific Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue by Type (2017-2022) & (USD Million)

Table 102. Asia-Pacific Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue by Type (2023-2028) & (USD Million)

Table 103. Asia-Pacific Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue by Application (2017-2022) & (USD Million)

Table 104. Asia-Pacific Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue by Application (2023-2028) & (USD Million)

Table 105. Asia-Pacific Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue by Region (2017-2022) & (USD Million)

Table 106. Asia-Pacific Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue by Region (2023-2028) & (USD Million)

Table 107. South America Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue by Type (2017-2022) & (USD Million)

Table 108. South America Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue by Type (2023-2028) & (USD Million)

Table 109. South America Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue by Application (2017-2022) & (USD Million)

Table 110. South America Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue by Application (2023-2028) & (USD Million)

Table 111. South America Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue by Country (2017-2022) & (USD Million)

Table 112. South America Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue by Country (2023-2028) & (USD Million)

Table 113. Middle East & Africa Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue by Type (2017-2022) & (USD Million)

Table 114. Middle East & Africa Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue by Type (2023-2028) & (USD Million)

Table 115. Middle East & Africa Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue by Application (2017-2022) & (USD Million)

Table 116. Middle East & Africa Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue by Application (2023-2028) & (USD Million)

Table 117. Middle East & Africa Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue by Country (2017-2022) & (USD Million)

Table 118. Middle East & Africa Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue by Country (2023-2028) & (USD Million)

List of Figures

Figure 1. Paclitaxel and Its Analogue in Anticarcinoma Drugs Picture

Figure 2. Global Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue Market Share by Type in 2021

Figure 3. Paclitaxel

Figure 4. Docetaxel

Figure 5. Liposome Paclitaxel

Figure 6. Protein-bound Paclitaxel

Figure 7. Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue Market Share by Application in 2021

Figure 8. Ovarian Cancer Picture

Figure 9. Breast Cancer Picture

Figure 10. Cervical Cancer Picture

Figure 11. Pancreatic Cancer Picture

Figure 12. Non-small Cell Lung Cancer Picture

Figure 13. Other Picture

Figure 14. Global Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Size, (USD Million): 2017 VS 2021 VS 2028

Figure 15. Global Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue and Forecast (2017-2028) & (USD Million)

Figure 16. Global Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue Market Share by Region (2017-2028)

Figure 17. Global Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue Market Share by Region in 2021

Figure 18. North America Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue (USD Million) and Growth Rate (2017-2028)

Figure 19. Europe Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue (USD Million) and Growth Rate (2017-2028)

Figure 20. Asia-Pacific Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue (USD Million) and Growth Rate (2017-2028)

Figure 21. South America Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue (USD Million) and Growth Rate (2017-2028)

Figure 22. Middle East and Africa Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue (USD Million) and Growth Rate (2017-2028)

Figure 23. Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Drivers

Figure 24. Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Restraints

Figure 25. Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Trends

Figure 26. Bristol-Myers Squibb Recent Developments and Future Plans

Figure 27. Celgene Corporation Recent Developments and Future Plans

Figure 28. Hospira Recent Developments and Future Plans

Figure 29. Biological E. Recent Developments and Future Plans

Figure 30. Taj Accura Recent Developments and Future Plans

Figure 31. Khandelwal Laboratories Recent Developments and Future Plans

Figure 32. Luye Pharma Recent Developments and Future Plans

Figure 33. Beijing Youcare Recent Developments and Future Plans

Figure 34. Beijing Union Recent Developments and Future Plans

Figure 35. Haiyao Recent Developments and Future Plans

Figure 36. Chuntch Recent Developments and Future Plans

Figure 37. Hengrui Medicine Recent Developments and Future Plans

Figure 38. Sanofi Recent Developments and Future Plans

Figure 39. Qilu Pharma Recent Developments and Future Plans

Figure 40. Shenzhen Main Luck Pharma Recent Developments and Future Plans

Figure 41. Jiangsu Aosaikang Pharma Recent Developments and Future Plans

Figure 42. CSPC Pharmaceutical Recent Developments and Future Plans

Figure 43. Aosaikang Pharm Recent Developments and Future Plans

Figure 44. Global Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue Share by Players in 2021

Figure 45. Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2021

Figure 46. Global Top 3 Players Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue Market Share in 2021

Figure 47. Global Top 10 Players Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue Market Share in 2021

Figure 48. Key Players Market Share Trend (Top 3 Market Share: 2020 VS 2021 VS 2022)

Figure 49. Global Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue Share by Type in 2021

Figure 50. Global Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Share Forecast by Type (2023-2028)

Figure 51. Global Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue Share by Application in 2021

Figure 52. Global Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Share Forecast by Application (2023-2028)

Figure 53. North America Paclitaxel and Its Analogue in Anticarcinoma Drugs Sales Market Share by Type (2017-2028)

Figure 54. North America Paclitaxel and Its Analogue in Anticarcinoma Drugs Sales Market Share by Application (2017-2028)

Figure 55. North America Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue Market Share by Country (2017-2028)

Figure 56. United States Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 57. Canada Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 58. Mexico Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 59. Europe Paclitaxel and Its Analogue in Anticarcinoma Drugs Sales Market Share by Type (2017-2028)

Figure 60. Europe Paclitaxel and Its Analogue in Anticarcinoma Drugs Sales Market Share by Application (2017-2028)

Figure 61. Europe Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue Market Share by Country (2017-2028)

Figure 62. Germany Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 63. France Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 64. United Kingdom Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 65. Russia Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 66. Italy Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 67. Asia-Pacific Paclitaxel and Its Analogue in Anticarcinoma Drugs Sales Market Share by Type (2017-2028)

Figure 68. Asia-Pacific Paclitaxel and Its Analogue in Anticarcinoma Drugs Sales Market Share by Application (2017-2028)

Figure 69. Asia-Pacific Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue Market Share by Region (2017-2028)

Figure 70. China Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 71. Japan Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 72. South Korea Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 73. India Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 74. Southeast Asia Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 75. Australia Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 76. South America Paclitaxel and Its Analogue in Anticarcinoma Drugs Sales Market Share by Type (2017-2028)

Figure 77. South America Paclitaxel and Its Analogue in Anticarcinoma Drugs Sales Market Share by Application (2017-2028)

Figure 78. South America Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue Market Share by Country (2017-2028)

Figure 79. Brazil Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 80. Argentina Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 81. Middle East and Africa Paclitaxel and Its Analogue in Anticarcinoma Drugs Sales Market Share by Type (2017-2028)

Figure 82. Middle East and Africa Paclitaxel and Its Analogue in Anticarcinoma Drugs Sales Market Share by Application (2017-2028)

Figure 83. Middle East and Africa Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue Market Share by Country (2017-2028)

Figure 84. Turkey Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 85. Saudi Arabia Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 86. UAE Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 87. Methodology

Figure 88. Research Process and Data Source